We studied 99 patients undergoing day-case urological surgery, allocated randomly to receive a sleep dose of either 1 % propofol or a mixture of equal volumes of 1 % propofol and 0.5 % methohexitone, and thereafter a standardized anaesthetic. With the exception of minor differences in intraoperative heart rate there were no significant differences between the two groups in induction properties and complications, intraoperative variables, rate of recovery or postoperative sequelae. (Br. J. Anaesth. 1996; 77: 213-216) Key words Anaesthesia, day-case. Anaesthetics i.v., propofol. Anaesthetics i.v., methohexitone. Anaesthetic techniques, induction.
Anaesthesia for day-case surgery is designed to provide rapid, uncomplicated recovery and discharge from hospital within a few hours of surgery. Although methohexitone has previously been used commonly, propofol is now considered the induction agent of choice for day-case anaesthesia because of its short recovery time and low incidence of postoperative sequelae [1] . However, compared with methohexitone, propofol produces a greater degree of cardiovascular and respiratory depression [2] and is more expensive. A combination of these two agents might accentuate their individual advantages, while minimizing the side effects. In this study, we have compared the properties of a mixture of propofol and methohexitone with those of propofol alone for day-case anaesthesia.
Patients and methods
After approval of the local Ethics Committee, we studied 99 patients undergoing day-case urological surgery; all gave informed consent and were ASA grade I or II, aged 16-70 yr. Exclusion criteria included specific contraindications to the study drugs or halothane anaesthesia.
After recording of baseline heart rate, systolic, diastolic and mean arterial pressures (MAP), and 2 O p S a suitable vein was cannulated. Patients were then allocated randomly to one of two groups, and each patient received a sleep dose of induction agent, with the end-point defined as loss of verbal contact. For patients in group A the syringe contained 9.5 ml each of methohexitone 5 mg ml 91 in 0.9 % sodium chloride and propofol 10 mg ml
91
, with 2 % lignocaine 1 ml. For those in group B the syringe contained 19 ml of propofol 10 mg ml 91 with 2 % lignocaine 1 ml. Neither investigator was aware of the patient's group, and it was not possible to differentiate visually between the contents of the syringes. All inductions and subsequent anaesthetics were carried out by one investigator (G. S. R.). The volume of agent needed to induce anaesthesia was noted, and also pain on injection, laryngeal spasm, cough, hiccup or apnoea. 
S
were recorded at 1-min intervals. Recovery scoring was conducted at 1-min intervals by one investigator (N. T.) using a scoring system validated in a previous study (appendix) [3] . Complications including nausea, vomiting, cough, hiccup or laryngeal spasm during the recovery period were recorded. Patients were transferred from the recovery area to the day ward, where any later complications were noted.
STATISTICAL ANALYSIS
Data were analysed using Student's t test, the chisquare test and Fisher's exact test, where appropriate. To analyse the recovery profiles, test statistics were constructed using general estimating equations, which were then used to fit a marginal proportional odds model [4] .
Results
There were no significant differences (P : 0.05) between the two groups in age, sex, preoperative cardiovascular variables or duration of anaesthesia ( mean volume of induction agent was 17.5 ml (range 12-20 ml) and for group B (propofol) 17 (11-20) ml. One patient in the propofol-methohexitone group exhibited marked spontaneous movement on induction. There were no significant differences in the occurrence of pain on injection, cough, laryngeal spasm, hiccup and apnoea on induction between the groups (table 2) .
Heart rate, MAP and 2 O p S were compared between the two groups for each of the first 10 min of anaesthesia. Heart rate was consistently higher in group A, but the difference was significant only at 1, 4, 9 and 10 min ( fig. 1 ). There were no other significant differences in these variables between the two groups at any time during anaesthesia or recovery. One patient in each group exhibited runs of ventricular ectopics during operation, which in both cases were treated successfully with i.v. lignocaine. One patient in the propofol group required atropine 0.3 mg i.v., after 5 min of anaesthesia to treat a bradycardia of 43 beat min
91
. Mean time to full recovery was similar in both groups (group A, 7 (SD 3.7) min, group B, (6.7 (3.1) min; ns). Comparison of the changes with time of the various elements of the recovery scores was made using a marginal proportional odds model. This revealed no difference in the time profiles of recovery between the two groups. There was no significant difference in complication rates during recovery (table 3) .
Discussion
In day-case anaesthesia, propofol is the "goldstandard" by which other induction agents are judged. However, its superior recovery profile [2, 5, 6] and relative infrequency of postoperative complications [1, 5, 7] are offset by its tendency to cause apnoea on induction [2, 5] and greater cardiovascular instability than other induction agents [2, 5, 6] .
Although specific information on the compatibility and stability of mixtures of propofol and methohexitone is not available, the data sheets on the use of these drugs did not suggest any obvious risk of physical or chemical incompatibility. It is recommended that, because of differences in pH, solutions of methohexitone should not be mixed with acid solutions. As the pH of propofol is 7.5, and that of the propofol-methohexitone mixture 8.9 [personal observation], physical incompatibility would be unlikely. The remarkably similar mean volumes of the induction agents (17.5 ml and 17 ml) provides further circumstantial evidence that no significant pharmacological interaction or change in drug potency took place in the drug mixture. The 1 : 2 Figure 1 Mean arterial pressure (MAP) and heart rate (mean, SD) before operation (Preop.) and during the first 10 min of anaesthesia for group A (propofol-methohexitone ( )) and group B (propofol ( )). *Significant difference (P < 0.05) in heart rate between groups. dilution of propofol in this study is well within the recommended maximum dilution of 1 : 5 using solutions such as 5 % glucose, and a previous study using mixtures of propofol and alfentanil did not cause any pharmacodynamic or physical instability [8] . For the purposes of this study, in view of the recommendation that dilutions of propofol should be used within 6 h, mixtures made more than 2 h previously were discarded. No visible layering, separation or development of particles occurred at any time in the drug mixtures. In this study, the behaviour of the propofolmethohexitone mixture was indistinguishable clinically from that of propofol alone during induction, maintenance and recovery. While the propofolmethohexitone group maintained a slightly higher heart rate during the first 10 min of anaesthesia ( fig.  1 ), clinically this was not noticeable or significant. Changes in MAP were similar in both groups ( fig. 1 ), although it might have been anticipated that the drug mixture would have caused less reduction in MAP because of the lesser hypotensive effect of methohexitone [2, 5, 6, 10] .
Compared with the results of previous studies (table 4), the propofol-methohexitone mixture compared favourably with methohexitone alone in all aspects except the incidence of apnoea on induction, which was higher with the drug combination, presumably reflecting the addition of propofol. In this study both groups had a lower incidence of pain on injection (because of the addition of lignocaine [12, 13] ), and of postoperative nausea and vomiting than described previously.
At present in the UK propofol costs £4.42 for a 200-mg ampoule. Methohexitone costs 41 p for a 50-mg dose from a 500-mg ampoule mixed to 0.5 % strength with water or saline; 20 ml of a 50 : 50 propofol-methohexitone mixture would therefore cost £2.62, a cost saving of £1.80 per patient compared with propofol. In a day-case unit treating 5000 patients per annum, this would represent an annual saving of approximately £9000 at current prices. The inconvenience of mixing methohexitone and preparing syringes was found by the authors to be negligible. 
